Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

AMGEN EPO COST-BENEFIT STUDY HAS BEEN SUBMITTED TO HCFA AND FDA, according to the firm. The study was conducted by the Battelle Institute's Battelle Human Affairs Research Center in Seattle under the direction of Roger Evans. Following meetings between Amgen and HCFA that formally began in June 1988, the study was commissioned in an effort to ensure that a reimbursement policy is issued upon approval of Amgen's recombinant erythropoietin product, Epogen. The product's approval is expected at any time. Amgen filed its Product License Application at the end of 1987 for anemias in dialysis patients with end-stage renal disease. Medicare's End-Stage Renal Disease Program covers the cost of dialysis treatment for patients of all ages. As part of the analysis, Evans devised a questionnaire to collect data not gathered from the standard medical protocols for clinical trials. The questionnaire addressed such issues as patient activity levels and ability to return to work. For example, nurses treating patients in Epogen clinical trials were asked to estimate daily patient activity at home and the amount of strain on family members due to an inactive patient. Amgen's U.S. marketing partner, Johnson & Johnson, has estimated the cost of Epogen therapy at $ 4,000-$ 8,000 per patient per year. The Battelle study was aimed at demonstrating that Epogen's treatment benefits balanced its steep price tag. In touting the product's cost effectiveness, Amgen has cited the "virtual elimination" of blood transfusions for Epogen patients. At the time the study was begun, Amgen had predicted that cost benefits from Epogen would be most significant for patients in earlier stages of dialysis because they would not be weakened by chronic anemia and thus not require long-term therapy to reverse debilitation. The market for erythropoeitin is a potentially large one. Clinical Nephrology Professor Joseph Eschbach of the University of Washington has predicted that once approved, EPO would be used by two-thirds to three-fourths of the 75,000 U.S. dialysis patients.(ITEM 200)#050928M001J59307# #970804M001XFCWP5# (ITEM 201)(COPYRIGHT) 1989 F-D-C Reports, Inc., The Pink Sheet, February 20, 1989

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts